Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Tax waiver on hybrids: These states offer tax breathers for EVs below Rs 20 lakh
- Data Centre firms brace for stronger controls and higher costs under DPDP Rules 2025
- Budget 2025: Agri industry calls for policy reforms to boost sustainability and rural growth
- India’s Green Commute Slows Down as EV Cabs Lose Spark
